Boje Kathleen M K, Jaworowicz David, Raybon Joseph J
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14260, USA.
J Pharmacol Exp Ther. 2003 Jan;304(1):319-25. doi: 10.1124/jpet.102.041533.
Nitric oxide (NO) and prostaglandins are inflammatory mediators produced during meningitis. The purpose of the present study was to pharmacologically inhibit cyclooxygenase-2 (COX-2) and inducible NO synthase (iNOS) to 1) explore the prostaglandin contribution to blood-cerebrospinal fluid barrier permeability alterations and 2) elucidate the in vivo concentration relationship between prostaglandin E2 (PGE2) and NO during experimental meningitis. Intracisternal injection of lipopolysaccharides (LPSs, 200 microg) induced neuroinflammation. Rats were dosed with nimesulide (COX-2 inhibitor), aminoguanidine (iNOS inhibitor), or vehicle. Evans blue was used to assess blood-cerebrospinal fluid barrier permeability. Meningeal NO and cerebrospinal fluid PGE2 were assayed using conventional methods. (Results are expressed as mean +/- S.E.M. of 5-9 rats/group.) Nimesulide failed to prevent blood-cerebrospinal fluid barrier disruption [cerebrospinal fluid Evans blue (micrograms per milliliter): control, 0.22 +/- 0.22*; LPS, 11.58 +/- 0.66; LPS + nimesulide, 10.58 +/- 0.86; *p < 0.05; ANOVA]. Although nimesulide decreased PGE2 (picograms per microliter; p < 0.01) in LPS + nimesulide rats (13.9 +/- 1.96) versus LPS + vehicle (73.8 +/- 12.4), meningeal NO production (picomoles/30 min/10(6) cells; p < 0.01) increased unexpectedly in LPS + nimesulide rats (439 +/- 47) versus LPS + vehicle rats (211 +/- 31). In contrast, aminoguanidine inhibited meningeal NO (picomoles/30 min/10(6) cells; p < 0.005) in LPS + aminoguanidine (111 +/- 20) versus LPS (337 +/- 48) but had no effects (p > 0.05) on PGE2. The in vivo relationship between PGE2 and NO was mathematically described by a biphasic, bell-shaped curve (r2 = 0.42; n = 27 rats; p < 0.0001). Based on these results, inhibition of prostaglandin synthesis not only fails to prevent blood-cerebrospinal fluid barrier disruption during neuroinflammation and but also promotes increased meningeal NO production. The in vivo concentration relationship between PGE2 and NO is biphasic, suggesting that inhibition of COX-2 alone may promote NO toxicity through enhanced NO synthesis.
一氧化氮(NO)和前列腺素是脑膜炎期间产生的炎症介质。本研究的目的是通过药物抑制环氧合酶-2(COX-2)和诱导型一氧化氮合酶(iNOS),以1)探讨前列腺素对血脑屏障通透性改变的作用,以及2)阐明实验性脑膜炎期间前列腺素E2(PGE2)与NO在体内的浓度关系。脑池内注射脂多糖(LPS,200微克)可诱导神经炎症。给大鼠分别给予尼美舒利(COX-2抑制剂)、氨基胍(iNOS抑制剂)或赋形剂。用伊文思蓝评估血脑屏障通透性。采用常规方法检测脑膜NO和脑脊液PGE2。(结果以每组5 - 9只大鼠的平均值±标准误表示。)尼美舒利未能预防血脑屏障破坏[脑脊液伊文思蓝(微克/毫升):对照组,0.22±0.22*;LPS组,11.58±0.66;LPS + 尼美舒利组,10.58±0.86;*p < 0.05;方差分析]。尽管尼美舒利使LPS + 尼美舒利组大鼠的PGE2(皮克/微升;p < 0.01)降低至(13.9±1.96),而LPS + 赋形剂组为(73.8±12.4),但LPS + 尼美舒利组大鼠脑膜NO的产生量(皮摩尔/30分钟/10⁶细胞;p < 0.01)相对于LPS + 赋形剂组大鼠(211±31)意外增加至(439±47)。相比之下,氨基胍抑制了LPS + 氨基胍组大鼠的脑膜NO(皮摩尔/30分钟/10⁶细胞;p < 0.005)至(111±20),而LPS组为(337±48),但对PGE2无影响(p > 0.05)。PGE2与NO在体内的关系通过双相钟形曲线进行数学描述(r² = 0.42;n = 27只大鼠;p < 0.0001)。基于这些结果,抑制前列腺素合成不仅不能预防神经炎症期间的血脑屏障破坏,反而会促进脑膜NO产生增加。PGE2与NO在体内的浓度关系是双相的,这表明单独抑制COX-2可能通过增强NO合成而促进NO毒性。